GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

The following is a summary of “Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized ...

GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...

New research, led by experts at the University of Nottingham, has found that certain types of medication used to treat ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

China: A recent real-world study has revealed promising benefits from combining sodium-glucose co-transporter 2 inhibitors ...

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.